Ibrutinib has also been shown to promote autophagic cell death in glioblastoma by a mechanism that appears to be mediated by the inhibition of the serine/threonine-specific protein kinase/mammalian target of rapamycin (Akt/mTOR) signaling pathway [92]. Here, MTOR is linked to glioblastoma.